Notice 30 May 2025 pharmaceuticals, fda, regulatory review, biotechnology, patent extension, loqtorzi

💊FDA Notice on Regulatory Review Period Determination for LOQTORZI

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LOQTORZI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

Learn More
Notice 14 May 2025 pharmaceuticals, fda, regulatory review, biologics, patent extension, omvoh

💊FDA's Patent Extension Determination for OMVOH

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OMVOH and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

Learn More
Notice 12 May 2025 healthcare, pharmaceuticals, fda, regulatory review, drug approval, patent extension

💊FDA Determines Regulatory Review Period for LITFULO Patent Extension

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LITFULO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

Learn More
Notice 12 May 2025 fda, regulatory review, pharmaceutical, patent extension, gilead sciences, sunlenca

💊FDA Notice on SUNLENCA Regulatory Review Period and Patent Extension

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SUNLENCA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

Learn More
Notice 1 Apr 2025 countervailing duties, international trade, regulatory review, usitc, chlorinated isocyanurates

⚖️Five-Year Review of Chlorinated Isocyanurates from China

The Commission hereby gives notice that it has instituted a review pursuant to the Tariff Act of 1930 ("the Act"), as amended, to determine whether revocation of the countervailing duty order on chlorinated isocyanurates from China would be likely to lead to continuation or recurrence of material injury. Pursuant to the Act, interested parties are requested to respond to this notice by submitting the information specified below to the Commission.

Learn More
Regulatory Compliance, Trade Agreements 8 Jan 2025 commerce, countervailing duties, international trade, regulatory review, usa, canada, softwood lumber

📊Preliminary Results on Softwood Lumber Duties Impacting Businesses

The U.S. Department of Commerce (Commerce) preliminary determines that a producer/exporter subject to the countervailing duty (CVD) order on certain softwood lumber from Canada, Interfor Sales & Marketing Ltd. (ISM), is cross-owned with Interfor Corporation, EACOM Timber Corporation (EACOM), Chaleur Forest Products Inc., and Chaleur Forest Products LP, four producers/exporters also subject to the countervailing duty (CVD) order on certain softwood lumber from Canada. Interested parties are invited to comment on these preliminary results.

Learn More